Daraxonrasib Demonstrates Initial Antitumor Activity in RAS-Mutant Lung Cancer

Daraxonrasib shows durable responses in RAS-mutant lung cancer

Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.

Newly approved pancreatic cancer drug shows promise in lung cancer

In an early clinical trial, one-third of patients with advanced lung cancer saw their tumors shrink. Larger trials are underway.

Daraxonrasib demonstrates initial antitumor activity in RAS-mutant lung cancer

Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.

Landmark pancreatic cancer drug shows potential against lung cancer too

Nature, Published online: 02 September 2026; doi:10.1038/d41586-026-02745-5Results bolster hopes that the drug daraxonrasib could prove effective against a variety of tumours.